{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:47:13Z","timestamp":1788346033056,"version":"build-2803163510"},"reference-count":13,"publisher":"Pharmaceutical Society of Japan","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2021,10,1]]},"DOI":"10.1248\/bpb.b21-00461","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T22:14:57Z","timestamp":1633040097000},"page":"1548-1550","source":"Crossref","is-referenced-by-count":15,"title":["Resolvin E1 Attenuates Chronic Pain-Induced Depression-Like Behavior in Mice: Possible Involvement of Chemerin Receptor ChemR23"],"prefix":"10.1248","volume":"44","author":[{"given":"Hiroe","family":"Suzuki","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Hokkaido University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Hokkaido University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuko","family":"Hitora-Imamura","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Hokkaido University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Ishimura","sequence":"additional","affiliation":[{"name":"Laboratory of Organic Chemistry for Drug Development, Graduate School of Pharmaceutical Sciences, Hokkaido University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Laboratory of Organic Chemistry for Drug Development, Graduate School of Pharmaceutical Sciences, Hokkaido University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Laboratory of Organic Chemistry for Drug Development, Graduate School of Pharmaceutical Sciences, Hokkaido University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Shuto","sequence":"additional","affiliation":[{"name":"Laboratory of Organic Chemistry for Drug Development, Graduate School of Pharmaceutical Sciences, Hokkaido University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Deyama","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masabumi","family":"Minami","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Hokkaido University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). <i>J. Clin. Psychiatry<\/i>, <b>76<\/b>, 155\u2013162 (2015).","DOI":"10.4088\/JCP.14m09298"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. <i>JAMA<\/i>, <b>292<\/b>, 338\u2013343 (2004).","DOI":"10.1001\/jama.292.3.338"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. <i>Am. J. Psychiatry<\/i>, <b>163<\/b>, 28\u201340 (2006).","DOI":"10.1176\/appi.ajp.163.1.28"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Deyama S, Shimoda K, Suzuki H, Ishikawa Y, Ishimura K, Fukuda H, Hitora-Imamura N, Ide S, Satoh M, Kaneda K, Shuto S, Minami M. Resolvin E1\/E2 ameliorate lipopolysaccharide-induced depression-like behaviors <i>via<\/i> ChemR23. <i>Psychopharmacology <\/i>(Berl.), <b>235<\/b>, 329\u2013336 (2018).","DOI":"10.1007\/s00213-017-4774-7"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. <i>Arch. Intern. Med.<\/i>, <b>163<\/b>, 2433\u20132445 (2003).","DOI":"10.1001\/archinte.163.20.2433"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Yalcin I, Barthas F, Barrot M. Emotional consequences of neuropathic pain: insight from preclinical studies. <i>Neurosci. Biobehav. Rev.<\/i>, <b>47<\/b>, 154\u2013164 (2014).","DOI":"10.1016\/j.neubiorev.2014.08.002"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Ishimura K, Fukuda H, Fujiwara K, Muromoto R, Hirashima K, Murakami Y, Watanabe M, Ishihara J, Matsuda T, Shuto S. Synthesis of resolvin E1 and its conformationally restricted cyclopropane congeners with potent anti-inflammatory effect. <i>ACS Med. Chem. Lett.<\/i>, <b>12<\/b>, 256\u2013261 (2021).","DOI":"10.1021\/acsmedchemlett.0c00639"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Decosterd I, Woolf CJ. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. <i>Pain<\/i>, <b>87<\/b>, 149\u2013158 (2000).","DOI":"10.1016\/S0304-3959(00)00276-1"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. <i>J. Neurosci. Methods<\/i>, <b>53<\/b>, 55\u201363 (1994).","DOI":"10.1016\/0165-0270(94)90144-9"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Arita M, Ohira T, Sun YP, Elangovan S, Chiang N, Serhan CN. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. <i>J. Immunol.<\/i>, <b>178<\/b>, 3912\u20133917 (2007).","DOI":"10.4049\/jimmunol.178.6.3912"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Serhan CN, Chiang N. Resolution phase lipid mediators of inflammation: agonists of resolution. <i>Curr. Opin. Pharmacol.<\/i>, <b>13<\/b>, 632\u2013640 (2013).","DOI":"10.1016\/j.coph.2013.05.012"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Xu ZZ, Zhang L, Liu T, Park JY, Berta T, Yang R, Serhan CN, Ji RR. Resolvins RvE1 and RvD1 attenuate inflammatory pain <i>via<\/i> central and peripheral actions. <i>Nat. Med.<\/i>, <b>16<\/b>, 592\u2013597 (2010).","DOI":"10.1038\/nm.2123"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Xu ZZ, Berta T, Ji RR. Resolvin E1 inhibits neuropathic pain and spinal cord microglial activation following peripheral nerve injury. <i>J. Neuroimmune Pharmacol.<\/i>, <b>8<\/b>, 37\u201341 (2013).","DOI":"10.1007\/s11481-012-9394-8"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/10\/44_b21-00461\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T07:02:16Z","timestamp":1633158136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/10\/44_b21-00461\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,1]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b21-00461","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,1]]},"article-number":"b21-00461"}}